Want to join the conversation?
$STJ said it expects to receive U.S. FDA approval for its MRI safe pacemakers and implantable cardioverter defibrillators in the second half of 2016 and in the first half of 2017. $STJ expects the approvals to boost its U.S. Cardiac Rhythm Management business which is currently pressured by product gaps.
Looking forward to the first $TSLA earnings after SolarCity acquisition.
What will be an ideal EPS range for $PZZA in its earnings today?